{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:57:41Z","timestamp":1790798261120,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2020,3,3]]},"abstract":"<jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Dyslipidemia guidelines recommend non\u2010high\u2010density lipoprotein cholesterol (non\u2010\n                      <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n                      \u2010C) and apolipoprotein B (ApoB) as additional targets of therapy and consider lipoprotein(a) a significant cardiovascular risk marker. The current analysis evaluates the effects of evolocumab on these parameters in various patient populations over time.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Data from 7690 patients, 4943 of whom received at least 1 dose of evolocumab, in 15 phase 2 and phase 3 studies with a duration ranging from 12\u00a0weeks to 5\u00a0years were pooled based on study length, patient population, and ezetimibe or placebo comparator groups. Patients could receive intensive statin therapy but not in the statin intolerance and monotherapy studies. The effects of evolocumab on percent change from baseline for non\u2010\n                      <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n                      \u2010C, ApoB, and lipoprotein(a) and achievement of treatment goals for non\u2010\n                      <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n                      \u2010C and ApoB were examined. Compared with placebo, evolocumab at both approved dosing regimens substantially reduced mean non\u2010\n                      <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n                      \u2010C (Q2W dose: \u221249% to \u221256%, monthly dose: \u221248% to \u221252%), mean ApoB (Q2W dose: \u221246% to \u221252%, monthly dose: \u221240% to \u221248%), and median lipoprotein(a) (Q2W dose: \u221222% to \u221238%, monthly dose: \u221220% to \u221233%) at 12\u00a0weeks. Effects on all 3 parameters persisted over 5\u00a0years. Lipid\u2010lowering effects were consistent among the patient populations examined (hypercholesterolemia\/mixed dyslipidemia, statin intolerance, heterozygous familial hypercholesterolemia, and type 2 diabetes mellitus).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      In this pooled analysis, evolocumab substantially reduced non\u2010\n                      <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n                      \u2010C, ApoB, and lipoprotein(a) compared with placebo. The effect was consistent and maintained in various patient populations over 5\u00a0years.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/jaha.119.014129","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T05:00:19Z","timestamp":1583125219000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Effect of Evolocumab on Non\u2010High\u2010Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies"],"prefix":"10.1161","volume":"9","author":[{"given":"Peter P.","family":"Toth","sequence":"first","affiliation":[{"name":"Preventive Cardiology CGH Medical Center Sterling IL"},{"name":"The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Baltimore MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Jones","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Baltimore MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Monsalvo","sequence":"additional","affiliation":[{"name":"Global Development Amgen Inc. Thousand Oaks CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Elliott\u2010Davey","sequence":"additional","affiliation":[{"name":"Global Development Amgen Ltd. Cambridge United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Antonio G.","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Global Development Amgen Inc. Thousand Oaks CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[{"name":"Polish Mother's Memorial Hospital Research Institute (PMMHRI) Lodz Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.02.003"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP171764.APPGL"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024611"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq386"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.10.106"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2008.118356"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.014"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.07.007"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.532499"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316222"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.10.021"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.018"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61399-4"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.4030"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.019"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500858"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu085"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1063"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902604"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2015.02.008"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.06.051"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy122"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P065334"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.01.40"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037184"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g3047"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.959247"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.07.752"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-017-1193-z"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.06.052"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1284078"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000441139.02102.80"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.08.1026"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003008"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002765"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.10.028"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.119.014129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T07:30:27Z","timestamp":1715585427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.119.014129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,3,3]]}},"alternative-id":["10.1161\/JAHA.119.014129"],"URL":"https:\/\/doi.org\/10.1161\/jaha.119.014129","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]},"assertion":[{"value":"2019-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e014129"}}